The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment

The First Affiliated Hospital of Anhui Medical University500 enrolled

Overview

The investigators conduct the real world study to explore the efficacy and safety of Albumin-binding taxol in lung cancer .

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female patients . 2. Confirmed by Histopathology or Cytology of Lung Cancer 3. Patients should be voluntary to the trial and provide with signed informed consent 4. The researchers believe patients can benefit from the study. Exclusion Criteria: 1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Albumin-binding taxol or its accessories 2. Pregnant or lactating women 3. Patients with Albumin-binding taxol contraindications 4. Patients of doctors considered unsuitable for the trial

Locations (1)

First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, China

Outcomes

Primary Outcomes

Progress free survival

Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.

Time frame: 1 year

Secondary Outcomes

Overall Survival

overall survival is defined as the length of time from random assignment to death or to last contact.

Time frame: 3 year

disease control rate

Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1

Time frame: 1 year

Objective tumor response rate

Objective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.